CME Group (CME) Projected to Post Quarterly Earnings on Wednesday

CME Group (NASDAQ:CME) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, July 23rd. Analysts expect the company to announce earnings of $2.98 per share and revenue of $1.68 billion for the quarter.

CME Group (NASDAQ:CME) last issued its earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 EPS for the quarter, beating the consensus estimate of $2.61 by $0.19. The company had revenue of $1.64 billion during the quarter, compared to the consensus estimate of $1.56 billion. CME Group had a return on equity of 14.03% and a net margin of 57.71%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period last year, the business posted $2.50 EPS. On average, analysts expect CME Group to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

CME Group Stock Performance

Shares of CME opened at $275.00 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.02 and a quick ratio of 1.02. The stock has a 50-day moving average of $276.31 and a 200-day moving average of $259.92. The company has a market cap of $99.10 billion, a PE ratio of 27.67, a P/E/G ratio of 4.83 and a beta of 0.44. CME Group has a one year low of $193.25 and a one year high of $290.79.

CME Group Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 25th. Shareholders of record on Monday, June 9th were paid a dividend of $1.25 per share. The ex-dividend date was Monday, June 9th. This represents a $5.00 dividend on an annualized basis and a yield of 1.82%. CME Group’s dividend payout ratio (DPR) is currently 50.30%.

Analyst Upgrades and Downgrades

CME has been the topic of a number of research analyst reports. Keefe, Bruyette & Woods boosted their target price on CME Group from $265.00 to $273.00 and gave the stock a “market perform” rating in a research note on Thursday, April 24th. Morgan Stanley boosted their target price on CME Group from $301.00 to $304.00 and gave the stock an “overweight” rating in a research note on Thursday, April 24th. UBS Group boosted their target price on CME Group from $290.00 to $305.00 and gave the stock a “buy” rating in a research note on Friday, April 25th. Citigroup boosted their target price on CME Group from $265.00 to $275.00 and gave the stock a “neutral” rating in a research note on Thursday, July 3rd. Finally, Wall Street Zen cut shares of CME Group from a “hold” rating to a “sell” rating in a report on Sunday. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, CME Group presently has an average rating of “Hold” and an average target price of $261.80.

Insider Buying and Selling at CME Group

In related news, insider Derek Sammann sold 4,650 shares of the firm’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $280.61, for a total transaction of $1,304,836.50. Following the completion of the sale, the insider owned 8,336 shares of the company’s stock, valued at $2,339,164.96. This trade represents a 35.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Larry G. Gerdes sold 2,000 shares of CME Group stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $264.10, for a total transaction of $528,200.00. Following the transaction, the director owned 38,651 shares in the company, valued at $10,207,729.10. This represents a 4.92% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,400 shares of company stock valued at $3,680,610. 0.30% of the stock is currently owned by company insiders.

Institutional Trading of CME Group

A hedge fund recently raised its stake in CME Group stock. Empowered Funds LLC grew its stake in CME Group Inc. (NASDAQ:CME) by 11.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,027 shares of the financial services provider’s stock after acquiring an additional 1,037 shares during the period. Empowered Funds LLC’s holdings in CME Group were worth $2,660,000 at the end of the most recent reporting period. Institutional investors own 87.75% of the company’s stock.

About CME Group

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.